OBESITYWEEK OPENING KEYNOTE SPEAKER
TUESDAY, NOV 5, 8:00 AM | View Session Information
William T. Cefalu, MD
Director, Division of Diabetes, Endocrinology and Metabolic Diseases | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |National Institutes of Health
Dr. William T. Cefalu is the Director of the Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH). Prior to joining the NIH in August 2019, Dr. Cefalu served as Chief Scientific, Medical & Mission Officer of the American Diabetes Association (ADA). From 2012 to 2017, Dr. Cefalu was the Executive Director, the George A. Bray, Jr. Endowed Super Chair in Nutrition and a professor at Louisiana State University’s (LSU’s) Pennington Biomedical Research Center (Pennington Biomedical) in Baton Rouge, LA.
During his nearly 35-year career as a physician caring for patients, a scientist and a health care expert, Dr. Cefalu has been an active leader within the endocrine and diabetes scientific and medical communities. As an extramural investigator, Dr. Cefalu had research support from the National Institutes of Health (NIH) for more than 25 years and was the principal investigator for two NIH-funded research centers. His clinical and basic science research focused specifically on interventions to improve the metabolic state of individuals with insulin resistance and type 2 diabetes, and in the cellular mechanisms for insulin resistance. In addition, over his career, he has played an active role in scholarly publications. From 2003 to 2011, he served as Associate Editor of Diabetes Care, the ADA’s clinical research and care journal, and Diabetes, the ADA’s basic science journal. From 2011-2017, he served as the editor-in-chief of Diabetes Care, and under tenure, Diabetes Care achieved the highest impact factor in its history.
ASMBS INTEGRATED HEALTH KEYNOTE SPEAKER
TUESDAY, NOV 5, 1:30 PM | View Session Information
Walter J. Pories, MD, FACS
Professor of Surgery, Biochemistry and Kinesiology at East Carolina University
Dr. Walter Pories, is a Professor of Surgery, Biochemistry and Kinesiology at East Carolina University. He has served as President of the Society for Environmental Health and Geochemistry, the Association of Program Directors in Surgery, the American Society for Metabolic and Bariatric Surgery, as the 2nd Vice President of the American College of Surgeons and Vice President of the Southern Surgical Association, as well as editor-in- chief and associate editor of several journals.
To improve the outcomes from bariatric surgery, he helped found and chaired the Surgical Review Corporation that developed the international Bariatric Surgery Centers of Excellence Program with its BOLD database that led to a reduction of the 90 day mortality in the US from about 10% to 0.3%. He was also the first to develop a postgraduate curriculum for graduate surgical education, published through four editions. His current research interest is the molecular explanation why type 2 diabetes clears within a matter of days following bariatric surgery. His group has had uninterrupted funding from the NIH for over three decades.
ASMBS MASON LECTURER
WEDNESDAY, NOV 6, 10:30 AM | View Session Information
Philip Schauer, MD
Professor of Surgery, Cleveland Clinic Lerner College of Medicine | Director, Cleveland Clinic Bariatric and Metabolic Institute
Dr. Philip Schauer is Professor of Surgery at the Cleveland Clinic Lerner College of Medicine, and Director of the Cleveland Clinic Bariatric and Metabolic Institute (BMI). He is past president of the American Society for Metabolic & Bariatric Surgery (ASMBS). He is former Chair and founder of ObesityWeek (2012-present) and Co-Chair of the Diabetes Surgery Summit (2007, 2015, 2019).
Dr. Schauer’s clinical interests include minimally invasive, foregut and bariatric surgery. He assisted the development of many complex foregut operations including laparoscopic gastric bypass, sleeve gastrectomy, anti-reflux surgery, paraesophageal hernia repair, and minimally invasive esophagectomy. He has performed more than 8000 operations for severe obesity and diabetes. His research interests include the pathophysiology of obesity and type 2 diabetes, and outcomes of minimally invasive and metabolic surgery. He has authored more than 350 scientific papers, 60 textbook chapters, and 3 textbooks related to obesity, bariatric/metabolic surgery and gastrointestinal surgery with more than 20,000 citations. He holds 4 patents for medical devices and is the recipient of the Cleveland Clinic 2015 Sones Award – highest honor for scientific innovation at the Cleveland Clinic. He is the recipient of the SAGES Pioneer in Surgical Endoscopy Award 2018.
TOS KEYNOTE SPEAKER
THURSDAY, NOV 7, 9:45 AM | View Session Information
Barbara E. Corkey, PhD
Why Have We Failed to Decrease Obesity and Diabetes?
Barbara E. Corkey has been the Zoltan Kohn Professor of Medicine and Vice Chair for Research in the Department of Medicine at Boston University. Dr. Corkey has been a leader in the fields of diabetes and obesity research for over 50 years with over 180 related publications and 40 years of continuous government research support. The Corkey laboratory has been engaged in research on obesity and diabetes, with a particular focus on metabolic signal transduction in ß-cells, adipocytes and hepatocytes, intercellular communication via circulating redox and the role of hyperinsulinemia in obesity and diabetes.
She does seminal work on the molecular basis of nutrient signaling that has a major impact on our current understanding of health and disease. Finally, Barbara has received numerous honors including the NIH MERIT Award, National Honorary Membership in Iota Sigma Pi, the National Honor Society of Women in Chemistry, Women in Science Lecturer at the Boston Museum of Science, the George Bray Founders Award of the Obesity Society, the Charles H. Best Lectureship and Award, University of Toronto and the Banting Medal for Scientific Achievement from the American Diabetes Association. A current major focus is on developing clinical/basic collaborative multi-PI grants to explore novel approaches to understand and treat metabolic diseases.